Hemispherian Starts Phase 1/2a Trial of GLIX1 Hemispherian started a Phase 1/2a GLIX1 trial on Apr 8, 2026; glioblastoma median OS is 12–15 months and 5-year survival ~7%, underscoring high unmet need.

Hemispherian Starts Phase 1/2a Trial of GLIX1: Hemispherian started a Phase 1/2a GLIX1 trial on Apr 8, 2026; glioblastoma median OS is 12–15 months and 5-year survival ~7%, underscoring high unmet need. 👈 Read full analysis #Hemispherian #GLIX1Trial #Glioblastoma #CancerResearch #ClinicalTrials

BioLineRx and Hemispherian Form Joint Venture to Advance GLIX1 for Glioblastoma Treatment BioLineRx Ltd. and Hemispherian AS have established a joint venture to develop GLIX1, a novel oral treatment for glioblastoma and other cancers, pending FDA approval.

BioLineRx and Hemispherian Form Joint Venture to Advance GLIX1 for Glioblastoma Treatment #Israel #Tel_Aviv #BioLineRx #GLIX1 #Hemispherian

Hemispherian's GLIX1 Receives FDA Clearance for Glioblastoma Treatment in Historic Move Hemispherian AS has received FDA IND clearance for GLIX1, the first drug targeting DNA repair vulnerabilities in glioblastoma and solid tumors.

Hemispherian's GLIX1 Receives FDA Clearance for Glioblastoma Treatment in Historic Move #Glioblastoma #Norway #Oslo #GLIX1 #Hemispherian

Hemispherian's GLIX1 Awarded FDA Orphan Drug Status for Malignant Glioma Treatment Hemispherian AS is pleased to announce that the FDA has conferred Orphan Drug Designation to GLIX1, a promising treatment for malignant glioma, enhancing its potential in oncology.

Hemispherian's GLIX1 Awarded FDA Orphan Drug Status for Malignant Glioma Treatment #Norway #Oslo #GLIX1 #Hemispherian #FDA_Orphan_Drug

Hemispherian's GLIX1 Receives Positive Opinion for Orphan Drug Designation in EU for Glioma Treatment Hemispherian AS announces a significant step with the EMA's positive opinion for GLIX1, a therapy for glioma, marking a vital milestone in cancer treatment advancement.

Hemispherian's GLIX1 Receives Positive Opinion for Orphan Drug Designation in EU for Glioma Treatment #Norway #Oslo #Glioma #GLIX1 #Hemispherian